Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic in MRI-safe pacemaker trial:

This article was originally published in Clinica

Executive Summary

Medtronic has begun an international clinical study of what it claims is the "first-ever" pacemaker to be developed and tested specifically for safe use in MRI machines under specified scanning conditions. Its EnRhythm MRI SureScan pacemaker includes modified hardware to minimise the level of energy transmitted through the lead/device connection point. It also includes a feature that can be programmed "on" before an MRI scan to eliminate the impact of MRI-generated electrical noise, which can prevent necessary pacing therapy or cause the device to over-sense and deliver unnecessary pacing therapy. The new study will involve around 350 patients and is expected to last for about 24 months. As for competitors, Pittsford, New York-based Biophan Technologies is aiming to develop biomedical devices capable of safely working with MRI systems.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT047561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel